Abstract Brentuximab vedotin (Adcetris, Seattle Genetics) is an antibody-drug conjugate (ADC) that joins an anti-CD 30 monoclonal antibody with the anti-tubulin agent monomethyl auristatin E via a dipeptide linker. It has demonstrated significant activity in CD 30-positive lymphomas and is currently approved by the US FDA for treatment of Hodgkin lymphoma that has relapsed following autologous stem-cell transplantation, or after two lines of chemotherapy in non-transplant candidates. Brentuximab vedotin has also been approved for the treatment of relapsed anaplastic large-cell lymphoma after front-line chemotherapy. We briefly review the biology of Hodgkin lymphoma, with a focus on the pathogenic role of CD 30 as well as the development of CD 30-targeted therapy. We also discuss both the current role of brentuximab vedotin in the management of relapsed and refractory Hodgkin lymphoma and the likely future developments for this agent.
Classical Hodgkin Lymphoma Biology
Originally described in 1832 by Sir Thomas Hodgkin, the disease that bears his name was not classified as a lymphoproliferative disorder until recently [1] . Hodgkin lymphoma (HL) is divided into classical HL (cHL) and nodule lymphocyte-predominant HL (NLPHL), with the former being overwhelmingly more common [2] . cHL itself is further classified into four subtypes based on histology: nodular sclerosis (the most common subtype), mixed cellularity, lymphocyte-depleted, and lymphocyte-rich. One of the peculiar aspects of HL is that the neoplastic clone, also known as the Hodgkin Reed-Sternberg (HRS) cell in cHL and the lymphocyte-predominant (LP) cell in NLPHL, is normally present only in small quantities in an affected lymph node, with the large majority of cells present in an inflammatory infiltrate comprising various other immune cells. As significant differences exist between the HRS and LP cells, the rest of the discussion is limited to the biology of cHL.
A detailed understanding of the underlying biology of cHL was hampered for years by both the paucity of the HRS cell and the uncertainty regarding its lineage. After years of controversy, the HRS cell was eventually shown to be an aberrant germinal or post-germinal B cell, based on gene expression studies as well as the fact that it demonstrates immunoglobulin rearrangement and somatic hypermutation [3, 4] . One of the historic difficulties of identifying the precise lineage of the HRS cell lay in the fact that its immunophenotype differed considerably from that of normal B cells. For instance, HRS cells often express markers that are not typically present on B cells, such as CD 15 and CD 30, but do not typically feature normal pan-B markers such as CD 19, CD 20, and CD 22 [5] .
This highly aberrant situation raises the obvious question of how cells derived from B cells end up being so different from their precursors. The answer appears to be due, in large part, to de-regulated expression of various transcription factors. While the main B-cell lineage factor, PAX5, is still expressed in the HRS cell [6] , many other transcription factors are significantly perturbed. For instance, the transcription factor NOTCH1, which normally directs immature lymphocytes towards the T-cell lineage while suppressing B-cell development, is aberrantly expressed in HRS and appears to play a significant role in the pathogenesis of cHL [7] . On the other hand, transcription factors that are involved in the expression of B-cell genes such as OCT2, BOB1, and PU.1 appear to be absent in the HRS cell [8, 9] . Other B-lineage transcription factors such as EBF1 and E2A may be present in low levels (in the case of EBF1) or are expressed but actively inhibited (in the case of E2A) [10] .
Another important characteristic of cHL is that the malignant HRS cell is present only in small quantities, while surrounded by an exuberant inflammatory background. In fact, the majority of the cells in cHL are normal reactive macrophages and T cells recruited by chemokines such as CCL17 that are secreted by HRS cells. The infiltrating T cells belong to the CD4? helper T (Th) and regulatory T (Treg) phenotypes; the presence of Tregs may be one of the reasons that the HRS cell is able to escape immune surveillance [11] . There is significant crosstalk between the HRS cells and the other surrounding cells, and this signaling is mediated primarily by various chemokines and cytokines, such as CCL5, interleukin (IL)-5, and CCL20, produced by both the HRS cell and other cells in the microenvironment [12] . Although the increased understanding of the microenvironment has not thus far translated into therapeutic advancement, a number of associated biomarkers (various cytokines, nuclear factor [NF]-jB, JAK/STAT 3, and various tyrosine kinases) have been found to be prognostic in cHL, and strategies targeting the microenvironment are under active development [13] .
Overview of Hodgkin lymphoma Treatment
The treatment of HL has been one of the great successes of modern medicine. Previously an inevitably fatal disease, advances in radiation and chemotherapy have rendered it one of the most curable malignancies, a fact made particularly important by the average youth of patients with HL. Although the prognosis for patients with HL varies significantly depending on the stage of disease as well as other associated risk factors (low serum albumin, low hemoglobin, male gender, age [45 years, stage IV disease, leukocytosis, and lymphopenia), the large majority of patients with HL achieve durable disease control via combination chemotherapy. Early-stage HL is associated with very high cure rates, and the 5-year survival is well in excess of 90 % across virtually all of the more recent studies [14] . However, in patients with advanced HL, the 5-year freedom from progression rate can be as low as 62 %, depending on their risk factors (see above), highlighting the need for improved therapies in this population [15] .
Front-line therapy in HL generally consists of combination chemotherapy with a four-drug regimen of doxorubicin (Adriamycin Ò ), bleomycin, vinblastine, and dacarbazine (ABVD), with or without radiation. ABVD was first described in 1975 [16] and has since evolved into the standard of care; a more intensive regimen that includes bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEA-COPP) decreases relapse rates, but does not result in increased overall survival compared with ABVD, and has more toxicities [17] . As compared with ABVD, alternative regimens such as MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) and Stanford (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) have been shown to be worse (in the case of MOPP) [18] or of similar efficacy (in the case of Stanford V) [19] in patients with advanced disease.
Despite the unequivocal successes that have been realized in the treatment of HL, a significant minority of patients, most of whom have poor-prognostic or advanced disease, will relapse after front-line therapy. Combination chemotherapy and radiation may be curative in a very select subset of patients with localized, late relapse, but the standard approach for the large majority of patients with relapsed HL is high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). This strategy can lead to a durable remission rate of 50 % [20] . Unfortunately, the prognosis for patients who relapse following ASCT has historically been very poor, with a median survival of 25 months [21] ; while allogeneic stem cell transplantation (allo-SCT) can be performed in a group of these patients, relapse rates remain high, even with this approach, with a progression-free survival (PFS) at 4 years of 24 % in one study [22] . Therefore, new therapies are urgently needed for the population of refractory and relapsed HL.
The Role of CD 30 in Hodgkin Lymphoma
While CD15 negativity is seen in a small but substantial percentage of HL, CD 30 positivity is nearly universal [23] . Aside from its near-ubiquitous presence in HL and anaplastic large-cell lymphoma (ALCL), CD 30 can also be expressed in a number of other lymphoma subtypes as well as germ cell tumors [24] . The physiologic role of CD 30 remains incompletely characterized, but the immediate downstream steps are well described. CD 30 is a member of the tumor necrosis factor (TNF) receptor (TNFR) family that appears to be a marker for activated lymphocytes, and has only limited expression in normal cells [25] . It is activated upon binding by the CD 30 ligand (CD 30L, also known as CD 153), which is a surface glycoprotein belonging to the TNF family and expressed on multiple immune cells. Signal transduction mediated by CD 30 can result in activation of multiple downstream pathways (including NF-jB), which are dependent on various factors, including the type of cell and the differentiation status [26] . The cytoplasmic domain of CD 30 itself has no intrinsic catalytic activity, and this process is contingent on recruitment of proteins belonging to the TNFR-associated factor (TRAF) family to the cytoplasmic portion of the receptors [27] . Of interest, CD 30 has been implicated in both cell proliferation and the seemingly opposite process of apoptosis, with prominent involvement of the pro-survival protein NF-jB [28] .
The role of CD 30-mediated cell signaling in HL HRS cells is unclear. Although HRS cells overexpress CD 30 and have activation of NF-jB pathways, stimulation of CD 30 in HL cell lines does not result in any change in either NF-jB activity or cell proliferation [29] . This suggests that NF-jB in HL is constitutively activated and independent of ligand receptor binding. In contrast to the lack of response to CD 30 stimulation in HL, activation of the CD 30 receptor in ALCL does result in downstream changes in gene expression as well as cell proliferation [30] , and NFjB is not constitutively active in ALCL [29] . The high level of CD 30 expression in HL cells, in conjunction with its relatively limited presence in normal tissues, has made it an attractive molecular target, and its importance in the pathophysiology of HL also suggests a potential therapeutic role for the abrogation of CD 30 signaling, an idea that has begun to be realized with brentuximab vedotin.
Targeting CD 30 in Hodgkin Lymphoma
Although various attempts at targeted therapies have been made in HL, the overwhelmingly greatest success has been achieved with the CD-30 targeted antibody-drug conjugate (ADC) brentuximab vedotin, which is the subject of this review. In this section, we briefly outline the history of CD 30-directed therapy in HL.
Given the restricted expression of CD 30 in benign tissues as well as its high rate of expression in a number of lymphoid malignancies, it was quickly identified as a potential therapeutic target for a monoclonal antibody. At least two naked anti-CD 30 monoclonal antibodies have been tested in the phase I setting. SGN-30, a mouse-human chimeric monoclonal antibody against CD 30, had demonstrated significant preclinical activity, which resulted in a phase I clinical trial of this agent in patients with refractory and relapsed CD 30-positive hematologic malignancies. A total of 24 patients, 21 of whom had HL, were enrolled, and SGN-30 was found to have only modest activity, although one patient with cutaneous ALCL had a complete response. No responses were seen in the HL population, and only 4 of 21 patients had disease stabilization, with the longest duration of stable disease being 16 months [31] . A phase II study of this agent was conducted in patients with refractory HL and ALCL and again showed no responses in the HL cohort, although 11 of 38 patients had disease stabilization for a period of up to 242 days [32] . MDX-060, a fully human monoclonal antibody against CD 30, was also assayed in a phase I/II trial and demonstrated similarly modest results in HL [33] .
Building upon the naked monoclonal antibody, other CD 30-based strategies have also been attempted in HL, including radioimmunotherapy and immunotoxins. Iodine-131-labeled murine anti-CD 30 was tested in 22 patients with refractory or relapsed HL and demonstrated a 27 % response rate with a single complete remission (CR), although all responses were fairly short-lived, with a median duration of only 4 months. Moreover, the treatment proved to be difficult to tolerate, as seven patients experienced grade 4 hematologic toxicity, tempering enthusiasm for this approach [34] . Multiple attempts at constructing a CD 30-based immunotoxin have been made. While clinically meaningful activity was seen first in the Ber-H2-SO6 immunotoxin, consisting of a murine anti-CD 30 antibody conjugated to Saporin-S6 [35] , as well as in Ki-4.dgA, consisting of a murine anti-CD 30 antibody conjugated to the ricin A-chain [36] , response rates were low and duration of response modest. Finally, an anti-CD16/CD 30 bispecific antibody designed to activate natural killer cells was also designed and tested in refractory cHL. Modest responses in early-phase studies were seen, but further study was hampered by the development of human antimouse antibodies (HAMA) and difficulty in producing adequate quantities of the agent [37] .
Brentuximab Vedotin
Brentuximab vedotin is an ADC consisting of the chimeric monoclonal anti-CD 30 antibody SGN-30 conjugated via a valine-citrulline peptide linker to the anti-tubulin agent monomethyl auristatin E (MMAE) [38] . A number of features are notable regarding this compound. Utilization of a chimeric rather than an entirely murine antibody decreased the development of HAMA, which was a significant problem with the previous agent Ki-4.dgA [36] . The choice of linker was also an important one; to minimize toxicity while preserving efficacy, the linker must remain stable while in circulation to prevent release of the free drug, yet must be readily cleaved once the entire molecule is internalized into the target cell. Linkers that require protease activity are generally more stable than those that are chemically cleaved upon exposure to the acid milieu of the lysosome. As expected, the dipeptide linker in brentuximab vedotin is highly stable until internalization into the target cell [39] .
Also of importance is the actual cytotoxic portion of the ADC which, in the case of brentuximab vedotin, is MMAE, a synthetic derivative of dolastatin 10. Dolastatin 10 is a powerful anti-mitotic agent originally isolated from the sea hare Dolabella auricularia and has been previously shown to be a potent inhibitor of microtubule polymerization [40] . However, in clinical trials, it demonstrated only very modest single-agent activity while causing significant hematologic toxicity [41] [42] [43] . MMAE was specifically engineered via total synthesis to have high hydrophilicity and stability under physiologic conditions [44] , and in vitro studies with the similar compound auristatin E (AE) showed it to be an extremely potent cytotoxic agent with activity in many different malignancies [45] . After demonstrating both in vitro and in vivo activity against CD 30-positive malignancies [46] , the drug compound cAC10-vcMMAE (now brentuximab vedotin) entered human clinical trials. The mechanism of action for brentuximab vedotin is depicted in Fig. 1 .
Clinical Data
The first phase I trial of brentuximab vedotin was published in 2010 and featured 45 patients with relapsed or refractory CD 30-positive lymphomas; 42 of these patients had HL, two had ALCL, and one had angioimmunoblastic T-cell lymphoma. The most common adverse events were fatigue, pyrexia, nausea, diarrhea, neutropenia, and peripheral neuropathy, and 1.8 mg/kg was found to be the maximum tolerated dose level [47] . Although obviously not the primary endpoint, the objective response rate (ORR) was 50 % at this dose, and the impressive activity prompted multiple phase II trials of brentuximab vedotin in both HL and ALCL.
A multicenter, open-label phase II study examining brentuximab vedotin in patients with HL that was relapsed or refractory after ASCT [48] demonstrated an ORR of 75 %, with 34 % of patients achieving a CR. Crucially, the CRs proved to be durable, with a median CR duration of 20.5 months, although the median PFS was only 5.6 months. Although CRs seen with brentuximab vedotin were durable, the available survival data from the study indicate that patients who achieve only a partial remission (PR) will likely relapse. There are no clinical or biological factors that can predict for CR or durable responses as yet. This trial also showed that brentuximab vedotin is well tolerated, with few grade 3-4 adverse events. The most notable adverse events were the emergence of peripheral sensory neuropathy (53/102 patients). The majority of the events were grade 1-2, and 80 % of the patients experienced improvement or resolution when the drug was discontinued.
On the basis of this trial, brentuximab was granted accelerated approval for treatment of HL after failure of ASCT or after failure of two multi-agent chemotherapy regimens in patients who are not candidates for ASCT. Retreatment with brentuximab vedotin has also been tested and found to be a viable strategy. A phase II trial was conducted in patients with CD 30-positive lymphomas who had previously achieved CR or PR on brentuximab vedotin [49] . These patients were taken off brentuximab vedotin for either toxicity, completion of 16 doses of therapy, or to proceed to ASCT or allo-SCT. They then developed relapsed CD 30-positive lymphomas, and were eligible to be retreated with brentuximab vedotin under this trial. Objective responses were seen in 17 of 24 patients (70 % ORR), and 39 % of the patients were able to achieve CR again.
As allo-SCT is the only potentially curative treatment for HL that has relapsed after ASCT, there has also been significant interest in whether not brentuximab vedotin can serve as an adequate bridge to an allo-SCT. This issue was explored in a multicenter retrospective study (City of Hope Medical Center and Fred Hutchinson Cancer Center) of 18 patients who were treated with brentuximab vedotin after prior ASCT failure and subsequently were eligible for reduced-intensity allo-SCT [50] . Most patients received a graft from an unrelated donor, and every patient in the study engrafted without delays. The incidence of acute graft-versus-host disease (GVHD) was 33.3 %, and the incidence of chronic GVHD was 56.3 %. Impressively, the overall survival after allo-SCT was 100 % at 1 year and PFS was 92.3 % at 1 year. This work was supported by another study using brentuximab vedotin as a bridge to allo-SCT in the UK [51] . Despite the brief follow-up period and small study size, these results are quite striking and suggest that brentuximab vedotin can be effectively utilized for disease cytoreduction prior to allo-SCT.
Finally, brentuximab vedotin has also been shown to be very active in patients relapsing after allo-SCT, a population that suffers from a particularly poor prognosis. In a multicenter retrospective analysis, the ORR was 50 %, with a CR rate of 38 %, and PFS of 7.8 months. The results mirrored those of the trial examining brentuximab vedotin after failure of ASCT, as the CRs were again markedly more durable than PRs; a PR was associated with a PFS of 34 weeks, whereas over 80 % of patients with a CR remained without evidence of disease at 1 year [52] .
Future Applications of Brentuximab Vedotin in HL
The available data clearly indicate that brentuximab vedotin has very impressive activity in relapsed and refractory HL. CRs obtained can be durable, especially given the extensive treatment history of the patients who have received this agent. Nevertheless, it also appears that, in spite of its strong activity as a single agent in the relapsed and refractory setting, it is not curative for all patients. Progression eventually occurs in the majority of patients while on this therapy, and prolonged administration also tends to result in cumulative neuropathy [53] . As mentioned previously, there are no known clinical or biological factors that predict for CR or prolonged duration of response. There are also no validated resistance mechanisms. Investigators at the City of Hope Medical Center showed that loss of CD 30 is probably not associated with resistance to brentuximab vedotin [54] . They performed core needle biopsies on patients who developed progressive disease while receiving brentuximab vedotin treatment, and the tumors showed persistent CD 30 expression by immunohistochemistry, despite their drug resistance. More translational research is needed to determine the resistance mechanisms to brentuximab vedotin. Another important research question is whether or not there is a role for brentuximab vedotin in patients with newly diagnosed HL or in patients who are experiencing a first relapse of their disease.
An open-label phase I study was conducted examining the combination of brentuximab vedotin with chemotherapy in the upfront treatment of advanced HL. Patients with advanced HL were either assigned to receive escalating doses of brentuximab vedotin (0.6, 0.9, or 1.2 mg/kg) along with standard doses of ABVD, or 1.2 mg/kg brentuximab vedotin along with AVD (withholding the bleomycin in this group). Both combinations were shown to be very active, as all 22 patients receiving ABVD and brentuximab vedotin and 24 of 26 patients receiving AVD and brentuximab vedotin became positron-emission tomography (PET)-negative after two cycles. While these rates compare favorably with historical controls, the combination of ABVD and brentuximab vedotin was found to have prohibitive pulmonary toxicity, with two patient deaths [55] . These results have prompted an ongoing, open-label, randomized, multi-center phase III trial of AVD and brentuximab vedotin versus ABVD as front-line therapy for advanced HL (http://www.clinicaltrials.gov as NCT01712490). There is also an ongoing phase II trial for brentuximab vedotin as a treatment for the first relapse of HL prior to ASCT (http://www.clinicaltrials.gov as NCT01393717). As patients with HL in first relapse with a reasonable performance status usually receive salvage chemotherapy followed by ASCT, it is hoped that the high response rates to brentuximab vedotin in later-line settings may result in its being an effective and relatively non-toxic bridge to ASCT.
Conclusion
One of the challenges in drug development for HL is that it is a disease in which the large majority of patients are cured, and consequently the therapeutic bar has been set high. Nonetheless, for the substantial number of patients with advanced-stage disease who relapse, the available salvage therapies are clearly inadequate. Therefore, as the first rationally designed targeted agent approved in HL, brentuximab vedotin is a much-needed addition to the therapeutic arsenal in HL. In light of its striking activity in relapsed and refractory disease, multiple clinical trials are being conducted that may very well confirm a role in earlier-line settings, and these results are eagerly awaited.
